Home Uncategorized Bausch + Lomb raised $ 630 million in an IPO, with no...

Bausch + Lomb raised $ 630 million in an IPO, with no expectations

54
0



Image source: Bausch + Lomb



Bausch + Lomb on Thursday estimated the initial public offering of shares below expectations, selling 35 million shares at a price of $ 18 per share with gross revenue of $ 630 million.


The deal gives the company a post-money market capitalization of $ 6.3 billion.


The eye care company promoted the deal in the range of $ 21 to $ 24 per share through a syndicate of banks led by Morgan Stanley and Goldman Sachs.


At the midpoint of the filed range, the deal would have received $ 787.5 million in gross revenue.


The action will start on Friday under the ticker BLCO on the New York and Toronto stock exchanges.



Promotions to monitor the rise of 5G wireless communications

Bausch Health, the parent company, first announced the spin-off of the eye care business in August 2000.


The timing for the company’s IPO has been unsatisfactory given recent market volatility, and falling prices could further stifle a year that has already been downgraded for new stock issues.



Investment dissertation



Click to enlarge


Investors may want to just look at the early action as this IPO opens on Friday. Stock index futures traded slightly lower after the Nasdaq and Dow posted the worst one-day drop since 2000.


Futures on the S&P 500, which fell 3.6% on Thursday for its second worst in 2022, fell 0.2% as of 5 a.m. ET.


We think the first day at Bausch + Lomb will be volatile with a large volume, and may only make sense for the most attentive day traders until stocks reach their level in the coming days and weeks.


However, in the long run we like the campaign as a macro game on demographics and brand awareness:


  • Leading brand awareness in the eye care market.
  • The global market for ophthalmic pharmaceuticals is $ 26 billion and growing.
  • The United Nations estimates that the population aged 65 and over will grow by 80% over the next 30 years.
  • Strong correlation between age and eye disease.
  • The International Diabetes Federation estimates that the prevalence of diabetes will increase by 50% over the next 25 years.
  • Diabetics are at increased risk for severe eye disease.
  • In 2021, the company’s revenue was $ 3.8 billion, up 10% from 2020.
  • A history of market-leading innovations.

_____


Source: Stock news



Share price data is provided by IEX Cloud with a 15-minute delay. Chart cost data is provided by TradingView with a 15-minute delay.








This article is first published on Source link

Previous articleThe CDC is investigating severe hepatitis in children
Next articleSidney Poitier: “One of the greatest legends of Hollywood.”